Press release
ESCLC Pipeline Assessment Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ ESCLC Pipeline Outlook Report [https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the ESCLC Pipeline Report
* In August 2025, Bristol-Myers Squibb announced a study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
* In August 2025, Amgen conducted a study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
* In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.
* DelveInsight's ESCLC pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for ESCLC treatment.
* The leading ESCLC Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
* Promising ESCLC Pipeline Therapies such as LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others.
Learn how leading ESCLC Companies are positioning themselves for success in the evolving pharmaceutical market-access the full report today!" @ ESCLC Clinical Trials Assessment [https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
ESCLC Emerging Drugs Profile
* Serplulimab+Chemo: Shanghai Henlius Biotech
Serplulimab (anti-PD-1 mAb) in combination with chemotherapy can be used for the treatment of ESCC, ES-SCLC, and GC. The Phase III clinical studies of Serplulimab in combination with chemotherapy for the treatment of Neo/adj. GC and LS-SCLC are on the fast track. Phase III clinical studies for sqNSCLC, ES-SCLC and LS-SCLC are global multi-centre trials. Currently, the drug is in Phase III stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).
* Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.
Vobramitamab duocarmazine (MGC018) is an investigational antibody-drug conjugate (ADC) comprised of a humanized B7-H3 monoclonal antibody (mAb) conjugated via a cleavable linker to the prodrug seco-DUocarmycin hydroxyBenzamide Azaindole (DUBA; licensed from Byondis, B.V.), with an average drug-to-antibody ratio (DAR) of ~2.7. DUBA is an alkylating agent that can damage DNA in both dividing and non-dividing cells, causing cell death. Vobra duo is designed to target solid tumors expressing B7-H3. Currently, the drug is in Phase II stage of its development for the treatment of Extensive-Stage Small Cell Lung Cancer (ESCLC).
* RYZ101: RayzeBio, Inc.
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2). RYZ101 is being evaluated in clinical studies for patients with SSTR+ gastroenteropancreatic neuroendocrine tumors who have previously been treated with Lu177-based somatostatin therapies and also in patients with extensive stage small cell lung cancer. RYZ101 is being combined with current standard of care therapy. Currently, the drug is in Phase I stage of its development for the treatment of of Extensive-Stage Small Cell Lung Cancer (ESCLC).
The ESCLC Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of ESCLC with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for ESCLC Treatment.
* ESCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* ESCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the ESCLC market.
From early-stage research to late-phase ESCLC Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don't miss this opportunity to stay informed-download now! @ ESCLC Treatment Drugs [https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
ESCLC Companies
Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
ESCLC Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Stay updated with the latest ESCLC Pipeline Insights-download our report for a deep dive into the next generation of therapeutics! @ ESCLC Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the ESCLC Pipeline Report
* Coverage- Global
* ESCLC Companies- Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC and others.
* ESCLC Pipeline Therapies- LY2510924, Carboplatin, Etoposide, Talazoparib, Temozolomide, Durvalumab, Cisplatin, Vorolanib, Atezolizumab and others.
* ESCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* ESCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest ESCLC Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!" @ ESCLC Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Extensive Stage Small Cell Lung Cancer (ESCLC): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Extensive-Stage Small Cell Lung Cancer (ESCLC) - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Serplulimab+Chemo: Shanghai Henlius Biotech
* Mid-Stage Products (Phase II)
* Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.
* Early Stage Products (Phase I)
* RYZ101: RayzeBio, Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
* Extensive Stage Small Cell Lung Cancer (ESCLC) Key Products
* Extensive Stage Small Cell Lung Cancer (ESCLC)- Unmet Needs
* Extensive Stage Small Cell Lung Cancer (ESCLC)- Market Drivers and Barriers
* Extensive Stage Small Cell Lung Cancer (ESCLC)- Future Perspectives and Conclusion
* Extensive Stage Small Cell Lung Cancer (ESCLC) Analyst Views
* Extensive Stage Small Cell Lung Cancer (ESCLC) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esclc-pipeline-assessment-report-2025-key-25-companies-and-breakthrough-therapies-shaping-the-future-landscape]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ESCLC Pipeline Assessment Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape here
News-ID: 4140726 • Views: …
More Releases from ABNewswire
Central Florida Notary Express, LLC Expands 24/7 Notary and Mobile Notary Servic …
Winter Park, FL - Central Florida Notary Express, LLC, a 24/7 provider of notary and mobile notary services and certified loan signings, announced expanded same-day coverage across the Greater Orlando area, including Orlando, Winter Park, Maitland, Casselberry, Winter Springs, DeLand, DeBary, Deltona, Sanford, and Lake Mary. The company offers on-site and curbside notarization for jurats, acknowledgments, power of attorney (POA), wills, health care surrogate forms, copy certifications, and real-estate loan…
Stafili Wine Cafe Brings the Heart of Greece to New York City - A Sophisticated …
Nestled in the vibrant neighborhoods of West Village and Tribeca, Stafili Wine Cafe is redefining New York's dining scene with an unforgettable Greek-inspired experience that blends exceptional wines, authentic Mediterranean cuisine, and an inviting, intimate atmosphere. Whether you're seeking a cozy date night, an after-work escape, or a refined venue for social gatherings, Stafili promises an indulgent journey through the flavors, aromas, and spirit of Greece - without ever leaving…
Solar Heroes Launches Premium Solar Control Window Film Solutions in Singapore, …
As Singapore continues to face soaring temperatures and rising energy costs, Solar Heroes, a premium solar control window film supplier and installer, is stepping up to deliver an innovative solution for homes, offices, and commercial spaces. With a commitment to sustainability, comfort, and performance, Solar Heroes is revolutionizing how Singaporeans experience indoor living through advanced solar control window film technology. More information can be found at https://solarheroes.sg.
Singapore - As Singapore…
Dlinxoutreach Unlocks the Power of AI Ecosystems for Companies Seeking Higher RO …
In today's fintech-driven digital economy, artificial intelligence is no longer a speculative technology; it is a monetizable growth driver. Global private investment in AI reached $252 billion in 2024, a 44.5% year-over-year increase according to Stanford's AI Index. In financial services, 77% of executives report achieving positive ROI within the first year of AI deployment, according to Bank Automation News. A Boston Consulting Group study further shows that one in…
More Releases for SCLC
Urban Edge Network Partners with SCLC for Social Justice and Economic Empowermen …
Image: https://www.abnewswire.com/upload/2025/07/02659c90ee7c5fd7ba17d849d467eb47.jpg
July 3, 2025 - Atlanta, GA - Urban Edge Network (UEN), a leading Black-owned sports and lifestyle media company, is proud to announce a groundbreaking partnership with the Southern Christian Leadership Conference (SCLC), one of the most storied civil rights organizations in American history. This collaboration aims to advance economic equity and social justice by harnessing the power of media, advertising, and community action.
The strategic alliance is designed to…
Small Cell Lung Cancer (SCLC) Therapeutics Market Research & Outlook 2020
Impact Analysis of Coronavirus Disease (Covid-19) on Small Cell Lung Cancer (SCLC) Therapeutics Market
Facto Market Insights published a title on “Small Cell Lung Cancer (SCLC) Therapeutics Market – 2020-2026”, to its collection. The study on the small cell lung cancer (SCLC) therapeutics market defines the analysis of all the segments, along with the market sizing, year-over-year growth analysis and structure of the industry. The research report also includes the analysis…
OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Fo …
Researchmoz added Most up-to-date research on "OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024" to its huge collection of research reports.
Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung…
Overview of Small cell lung cancer (SCLC) Industry : Market Development, Analysi …
ALBANY, NY, April 5, 2017 : ResearchMoz presents professional and in-depth study of "Small cell lung cancer (SCLC)- Market Insights, Epidemiology and Market Forecast-2023".
DelveInsights Small cell lung cancer (SCLC) - Market Insights, Epidemiology and Market Forecast-2023 Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers…
Small cell lung cancer (SCLC)- Market Insights, Epidemiology and Market Forecast …
DelveInsights Small cell lung cancer (SCLC) - Market Insights, Epidemiology and Market Forecast-2023 Reports provides an overview of the disease and global market trends of the Indication for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Small cell lung cancer (SCLC) forecasted market share for ten years to 2023…
Small Cell Lung Cancer (SCLC) Treatment Market Revenue and Value Chain 2016-2026
According to the World Health Organization (WHO), 8.2 million people died from cancer around the world in 2012, and cancer is now one of the leading causes of death. Lung cancer is the leading cancer type and caused 1.59 million deaths in 2012.
Small cell lung cancer is two types -
Oat cancer
Combiner small cell cancer
The major risk factors for small cell lung…
